
Manchester Advanced Trauma Training 

## Annual Report 

1[st] February 2025 – 31[st] January 2026 




## Contents 

**Annual Summary of the Charity** ............................................................................................................ 3 **Activity** .................................................................................................................................................... 3 Future plans ........................................................................................................................................ 3 

2 | P a g e 



## Annual Summary of the Charity 

Manchester Advanced Trauma Training (MATT) became a Charitable Incorporated Organisation on 10th February 2022.  There are five Trustees of the Charity.  The object of Manchester Advanced Trauma Training is the advancement of health for public benefit by educating healthcare professionals about major trauma. 

## Activity 

The charity has not been active in 2025-6 whilst charity trustees have been busy with other activities. MATT is run by volunteers with full-time healthcare positions within the NHS.  It is becoming increasingly challenging to deliver trauma courses.  From a financial perspective from MATT has seen increasing costs, particularly of cadaveric specimens, and decreasing study budgets available to healthcare professionals as well as educational budgets available from industry.  The volunteers who run the charity or under increasing pressure from their NHS practices and time to run courses is very sparse. The administrative load to running a suite of courses is very large. 

## Future plans 

In January 2027, MATT will run a two-day cadaveric course focused on paediatric trauma at the Manchester Simulation and Surgical Skills Centre, University of Manchester. This will follow a similar format to the previous adult trauma course, FireFighting for Surgical Teams, run in previous years by MATT. 

3 | P a g e 



||**Charity Name**<br>|**Charity Name**<br>|**Charity Name**<br>|**No (if any)**|**CC16a**|
|---|---|---|---|---|---|
||**For the period**<br>**from**|Period start date<br>2/1/2025|**To**<br>|Period end date<br>1/31/2026||
|||||||
|**Section A Receipts and payments**||||||
|**A1 Receipts**<br>**- #**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**_Sub total_                               -**<br>**_Total receipts_                            -**<br>**A3 Payments**<br>-<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**_Sub total_                                -**<br>**-**<br>**-**<br>**_Sub total_                                -**<br>**_Total payments_                            -**<br>**_Net of receipts/(payments)_                            -**<br>**A5 Transfers between funds**<br>**-**<br>**A6 Cash funds last year end**<br>**-**<br>**_Cash funds this year end_                            -**<br>**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**_Sub total_**_(Gross income for AR)_<br>**A2 Asset and investment sales,**<br>**(see table).**<br>**A4 Asset and investment**<br>**purchases, (see table)**||**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Restricted**<br>**funds**|**to the nearest £**<br>**Endowment**<br>**funds**|**Total funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Last year**<br>**to the nearest £**|
||||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**-**|**26,634**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**26,634**|
|||||||
||||**-**<br>**-**<br>**-**|**-**||
|||||**-**|**-**|
|||||**-**|**-**|
|||||||
||||**-**|**-**|**26,634**|
|||||||
||||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**||**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||**-**|**-**|
|||||||
||||**-**<br>**-**<br>**-**|**-**||
|||||**-**||
|||||**-**|**-**|
|||||||
||||**-**|**-**|**-**|
|||||||
|||**-**|**-**<br>**-**<br>**-**<br>**-**|**-**|**26,634**|
|||**-**||**-**|**-**|
|||**-**||**-**|**-**|
|||**-**||**-**|**26,634**|





## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B3 Investment assets**<br>**B5 Liabilities**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>Signed by one or two trustees on<br>behalf of all the trustees|**Details**<br>**Details**<br>**Details**<br>**Details**<br>**Details**<br>Signature<br>#VALUE!<br>#VALUE!<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))|**to nearest £**<br>**to nearest £**<br>**26,633**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**26,633**<br>**-**<br>Agreement Error<br>OK<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>Stella Smith<br>Ian Tyrrell-Marsh<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**|**to nearest £**<br>**Endowment**<br>**funds**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**to nearest £**<br>**Endowment**<br>**funds**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
||#VALUE!|Stella Smith|10/22/2026|
||#VALUE!|Ian Tyrrell-Marsh|10/22/2026|



